Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
capecitabine + lapatinib + trebananib
- Development stage
- Phase 1
- Lead developer
- GSK
- Modality
- Small Molecules, Peptides
- Administration
- Oral
01
Overview
This is a theoretical combination of three distinct drugs: lapatinib, an oral, reversible, dual inhibitor of epidermal growth factor receptor ErbB1 (EGFR) and human epidermal growth factor receptor type 2 ErbB2 (HER2); capecitabine, an oral chemotherapy agent that is metabolized to 5-FU (5-fluorouracil) in the body; and trebananib, a peptide-Fc fusion protein that neutralizes the receptor-ligand interaction between Tie2 and angiopoietin-1/2, functioning as an angiogenesis inhibitor. While the combination of lapatinib and capecitabine is FDA-approved for treating advanced or metastatic HER2-positive breast cancer, the specific three-drug combination of capecitabine + lapatinib + trebananib does not appear to be an established or widely studied regimen based on the provided search results.
- Other names
- trebananib + capecitabine + lapatinib
02
Targets
ANGPT1 (Angiopoietin-1)ANGPT2 (Angiopoietin-2)EGFR (Epidermal growth factor receptor)ERBB2 (Erb-b2 receptor tyrosine kinase 2)TS (Thymidylate synthase)TEK (Tie2)
Beyond the preview
Go deeper on capecitabine + lapatinib + trebananib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on capecitabine + lapatinib + trebananib.